Literature DB >> 8032634

Characterization of the prostaglandin E2 sensitive (EP)-receptor in the rat isolated trachea.

S J Lydford1, K McKechnie.   

Abstract

1. Using a range of natural and synthetic prostanoid receptor agonists and antagonists, we have shown that the rat isolated trachea contains a heterogeneous population of prostaglandin receptor sub-types mediating both relaxation and contraction of the smooth muscle. Prostaglandin E2 (PGE2) elicits smooth muscle relaxation of pre-contracted preparations, the responses being well defined, with a mean potency (p[A50]) of 7.81 +/- 0.05. 2. 11-deoxy PGE1 16,16-dimethyl PGE2 and misoprostol were all full agonists at this receptor, whilst AH13205 was a low potency agonist, and sulprostone was inactive. 3. The EP1 receptor antagonist, AH6809 (5 microM), and the selective DP receptor antagonist, BW A868C (0.1 microM), had no significant effect on the concentration-effect (E/[A]) curves to PGE2. 4. The putative EP4-receptor antagonist, AH23848B, produced non-competitive antagonism of the PGE2 response curves; pA2 values of 5.07 +/- 0.15 and 5.24 +/- 0.19 were obtained at concentrations of 30 microM and 100 microM respectively. 5. The synthetic thromboxane A2 mimetic, U46619, caused smooth muscle contractions, with a mean p[A50] of 6.90 +/- 0.11. This response was antagonized by the TP receptor antagonist, GR32191B, yielding a mean pA2 of 8.31. 6. At concentrations of 1 microM and above, prostaglandin D2 (PGD2) and the IP-receptor agonist, cicaprost, generally elicited concentration-dependent relaxations of the rat trachea. Prostaglandin F2 alpha (PGF2 alpha) was without affinity or efficacy. 7. These data suggest that the rat isolated trachea contains EP-receptors, TP-receptors, and few, if any DP, IP or FP-receptors. The inactivity of sulprostone (EP3/EPj receptor selective) and the low potency of AH1 3205 (EP2-receptor selective) suggest that the rat trachea contains an atypical EP-receptor that does not conform to the current classification system.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8032634      PMCID: PMC1910312          DOI: 10.1111/j.1476-5381.1994.tb13042.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  12 in total

1.  Cloning and expression of a cDNA for mouse prostaglandin E receptor EP3 subtype.

Authors:  Y Sugimoto; T Namba; A Honda; Y Hayashi; M Negishi; A Ichikawa; S Narumiya
Journal:  J Biol Chem       Date:  1992-04-05       Impact factor: 5.157

2.  Cloning and expression of cDNA for a mouse EP1 subtype of prostaglandin E receptor.

Authors:  A Watabe; Y Sugimoto; A Honda; A Irie; T Namba; M Negishi; S Ito; S Narumiya; A Ichikawa
Journal:  J Biol Chem       Date:  1993-09-25       Impact factor: 5.157

3.  AH23848: a thromboxane receptor-blocking drug that can clarify the pathophysiologic role of thromboxane A2.

Authors:  R T Brittain; L Boutal; M C Carter; R A Coleman; E W Collington; H P Geisow; P Hallett; E J Hornby; P P Humphrey; D Jack
Journal:  Circulation       Date:  1985-12       Impact factor: 29.690

4.  Prostaglandin E receptor subtypes in smooth muscle: agonist activities of stable prostacyclin analogues.

Authors:  Y J Dong; R L Jones; N H Wilson
Journal:  Br J Pharmacol       Date:  1986-01       Impact factor: 8.739

5.  AH6809, a prostaglandin DP-receptor blocking drug on human platelets.

Authors:  R J Keery; P Lumley
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

6.  Characterization of prostanoid relaxant/inhibitory receptors (psi) using a highly selective agonist, TR4979.

Authors:  P J Gardiner
Journal:  Br J Pharmacol       Date:  1986-01       Impact factor: 8.739

7.  The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater.

Authors:  M G Buzzi; M A Moskowitz
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

8.  Investigation of the prostaglandin E (EP-) receptor subtype mediating relaxation of the rabbit jugular vein.

Authors:  R A Lawrence; R L Jones
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

9.  Studies on the characterisation of prostanoid receptors: a proposed classification.

Authors:  I Kennedy; R A Coleman; P P Humphrey; G P Levy; P Lumley
Journal:  Prostaglandins       Date:  1982-11

10.  GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro.

Authors:  P Lumley; B P White; P P Humphrey
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

View more
  13 in total

1.  Role of PGE(2) in protease-activated receptor-1, -2 and -4 mediated relaxation in the mouse isolated trachea.

Authors:  R S Lan; D A Knight; G A Stewart; P J Henry
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

2.  Chronic systemic administration of salmeterol to rats promotes pulmonary beta(2)-adrenoceptor desensitization and down-regulation of G(s alpha).

Authors:  P A Finney; L E Donnelly; M G Belvisi; T T Chuang; M Birrell; A Harris; J C Mak; C Scorer; P J Barnes; I M Adcock; M A Giembycz
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

3.  The cyclo-oxygenase-dependent regulation of rabbit vein contraction: evidence for a prostaglandin E2-mediated relaxation.

Authors:  C Rouaud; M Delaforge; M Anger-Leroy; G Le Filliatre; M Finet; R Hanf
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

4.  PGE2 maintains the tone of the guinea pig trachea through a balance between activation of contractile EP1 receptors and relaxant EP2 receptors.

Authors:  J Säfholm; S-E Dahlén; I Delin; K Maxey; K Stark; L-O Cardell; M Adner
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

5.  Prostanoid receptors involved in the relaxation of human bronchial preparations.

Authors:  X Norel; L Walch; C Labat; J P Gascard; E Dulmet; C Brink
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

6.  Prostanoid receptors involved in the relaxation of human pulmonary vessels.

Authors:  L Walch; C Labat; J P Gascard; V de Montpreville; C Brink; X Norel
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

7.  Replacement of the carboxylic acid group of prostaglandin f(2alpha) with a hydroxyl or methoxy substituent provides biologically unique compounds.

Authors:  D F Woodward; A H Krauss; J Chen; D W Gil; K M Kedzie; C E Protzman; L Shi; R Chen; H A Krauss; A Bogardus; H T Dinh; L A Wheeler; S W Andrews; R M Burk; T Gac; M B Roof; M E Garst; L J Kaplan; G Sachs; K L Pierce; J W Regan; R A Ross; M F Chan
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

8.  Albuterol-induced downregulation of Gsalpha accounts for pulmonary beta(2)-adrenoceptor desensitization in vivo.

Authors:  P A Finney; M G Belvisi; L E Donnelly; T T Chuang; J C Mak; C Scorer; P J Barnes; I M Adcock; M A Giembycz
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

9.  Pharmacological studies on prostanoid receptors in the rabbit isolated saphenous vein: a comparison with the rabbit isolated ear artery.

Authors:  S J Lydford; K C McKechnie; I G Dougall
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

Review 10.  Prostanoid receptor antagonists: development strategies and therapeutic applications.

Authors:  R L Jones; M A Giembycz; D F Woodward
Journal:  Br J Pharmacol       Date:  2009-07-15       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.